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TITLE OF CASE  
A Rare Case of Eosinophilic Granulomatosis with Polyangiitis in two patients with Alpha-1Antitrypsin 
Deficiency (PiSZ).  
Jordan Moxey  Dr. Emma V Low* Dr. Alice M Turner 
SUMMARY Up to 150 words summarising the case presentation and outcome  
We present two cases of eosinophilic granulomatosis with polyangiitis occurring with alpha-
1antitrypsin deficiency, both PiSZ phenotype. The simultaneous occurrence of these two conditions 
has seldom been described in the literature, despite evidence of an association between alpha-1-
antitrypsin deficiency and other forms of vasculitis. Both patients had pulmonary involvement and 
reported intermittent exacerbations of vasculitic symptoms. Both patients were managed on low 
dose oral steroids and azathioprine remaining well with occasional exacerbations. It is important to 
consider whether there is an association between eosinophilic granulomatosis with polyangiitis and 
alpha-1-antitrypsin deficiency, as this may lead to more severe pulmonary symptoms during 
exacerbations. If a genetic association between the two conditions is found, clinicians should be 
aware of the possible need to screen for alpha-1antitrypsin deficiency in appropriate patients.    
BACKGROUND Why you think this case is important – why you decided to write it up  
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg Strauss syndrome, is 
a rare systemic inflammatory disease of small and medium-sized blood vessels. It is associated with 
eosinophilia, asthma and damage to the skin, nerves, lungs, kidneys and heart due to vasculitis.[1,2] 
No widely accepted diagnostic criteria currently exists for EGPA, though a number of classification 
criteria are available.[3,4] Alpha-1-antitrypsin deficiency (AATD) is a common but under-diagnosed 
genetic disorder that causes relative deficiency of the liver enzyme antitrypsin, which protects the 
lung against proteinases. AATD is caused by mutations in the SERPINA1 gene located on the long arm 
of chromosome 14 (14q31-32.3), which are inherited in an autosomal codominant manner.[5,6] The 
highly polymorphic nature of this gene means that over 90 protein variants (known as PI* types) 
have been identified.[7]    
The deficiency phenotypes PI*SZ and PI*ZZ are associated with greater severity of disease in 
AATD.[8] An association between AATD phenotype and a number of forms of vasculitis has been 
outlined in the literature. Both Mahr and Morris and colleagues identify an association between 
carriage of the Z deficiency allele and granulomatosis with polyangiitis (GPA), also known as 
Wegner’s granulomatosis.[9,10] Mahr and colleagues concluded that both SZ and ZZ phenotypes 
increased the risk of GPA in AATD.[9] Both alleles are over-represented in patients with anti-
neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis compared to normal 
populations.[9,11] ANCA positive status is found in many vasculitic syndromes including EGPA.[2] 
Therefore, it is possible that a number of EGPA patients may express S and Z deficiency alleles, as 
part of undiagnosed AATD. Here we present two such cases, with both patients expressing PI*SZ 
AATD phenotypes in conjunction with EGPA.    
CASE PRESENTATION Presenting features, medical/social/family history  
Patient 1.  An 82 year old Caucasian female presented to hospital with a two-week history of 
lethargy, shortness of breath, anorexia, back pain, myalgia and paraesthesia in the arms and legs. 
She had noticed a mottled, red rash on the medial aspect of her left leg a week previously, which 
had resolved prior to presentation.  The patient had been diagnosed with asthma 30 years 
previously, later being diagnosed with chronic bronchitis and alpha-1-antitrypsin deficiency (PI*SZ 
type). She is a lifelong non-smoker.  On inspection, there were no skin changes identified, the chest 
was clear on auscultation and heart sounds were normal with no added sounds. On abdominal 
examination, there was mild tenderness in the epigastric and umbilical regions. On examination of 
the peripheral nervous system, there was normal tone, power, sensation, reflexes and coordination 
in both the upper and lower limbs. After initial assessment the clinical suspicion was of an underlying 
malignancy.    
Patient 2.  A 36 year old Caucasian woman was admitted to hospital with a 6-week history of 
increasing dyspnoea, cough, fatigue, palpitations, back pain and night sweats. Recently she had 
suffered with persistent nausea and had lost weight. There was pain in her elbow joints, there were 
no other changes to her joints or skin. She had a past medical history of post-natal jaundice, juvenile 
arthritis, perennial rhinitis, chronic sinusitis, hay fever, endometriosis and late onset asthma. She 
had a paternal second cousin with haemachromatosis and maternal second cousin Wegener’s 
Granulomatosis. She took salbutamol as required and beclomethasone inhalers for her asthma.  She 
was a non-smoker.  On examination, patient was tachycardic and appeared considerably short of 
breath at rest. Auscultation of the chest was clear and general examination was normal apart from a 
low grade pyrexia.    
INVESTIGATIONS If relevant  
Patient 1.  Blood tests revealed an unusually high eosinophil count of 24.4x109/L, deranged liver 
function tests; ALP 255U/L, ALT 45U/L, raised inflammatory markers; white cell count (WCC) 
37.4x109/L, C-reactive protein (CRP) 105mg/L. Creatinine kinase was 330U/L. Serology showed 
positive anti-nuclear antibodies (ANA), positive anti-nuclear antibodies (ANCA), titre = 1/50, (pANCA 
or cANCA pattern unknown), negative myeloperoxidase antibodies (MPO) and negative proteinase 3 
antibodies. Her alpha-1-antityrpsin level was 0.83µM. A CT of the thorax, abdomen and pelvis 
showed bilateral apical scarring and small hilar and mediastinal calcified lymph nodes but no other 
obvious abnormalities.     
Patient 2.  Resting saturation was 93-96%, peak flow was 450 L/min and FEV1/FVC ratio had reduced 
from 2.6/2.7L to 2.15/2.2L. Serum testing demonstrated raised WCC; 15.9x109/L and raised 
eosinophils; 5.6x109/L with neutrophils of 7.6x109/L. Liver function was mildly deranged ALP 
121U/L, ALT 42U/L and erythrocyte sedimentation rate (ESR) was markedly raised at 103mm/hr. 
Serology showed negative ANCA. Sputum cultures, thyroid function tests, urea and electrolytes were 
normal.   
Urinalysis showed a trace of blood and protein but no haematuria. A chest X-ray showed significant 
bilateral patchy infiltrates, particularly of the upper lobes with a slightly prominent left hilum. 
Bronchoscopy and transbronchial biopsy was inconclusive.    
DIFFERENTIAL DIAGNOSIS If relevant       
TREATMENT If relevant   
Patient 1. The patient was treated with three doses of intravenous methylprednisolone 500 mg and 
a prolonged reducing course of oral prednisolone, with the option of introducing intravenous 
cyclophosphamide if symptoms did not resolve. On review in clinic two weeks after discharge, the 
majority of her symptoms had resolved, aside from mild residual paraesthesia in the fingers and 
toes. Her Birmingham Vasculitis Assessment Score had improved from 15 to 0 and the eosinophil 
count had normalised from 24.4 to 0.2. Intravenous cyclophosphamide was therefore not required 
and the patient was started on azathioprine at a dose of 2 to 3mg/kg, for up to five years.    
Patient 2. The patient was managed with oral prednisolone. This led to a rapid improvement in 
symptoms, serum tests normalised, aside from liver function which remained slightly deranged. The 
patient was started on long-term, low dose prednisolone 5mg OD and azathioprine 75mg OD. On 
review in clinic two weeks later, a diagnosis of EGPA with pulmonary and sinus involvement was 
made.   
OUTCOME AND FOLLOW-UP    
Patient 1. Eighteen months on from her initial presentation, the patient reported marked 
symptomatic improvement. Prednisolone was continued for 18 months and gradually stopped. She 
remains on azathioprine alone, at a dose of 100mg OD. On review, the patient reports regular 
exacerbations of her respiratory symptoms, occurring approximately every two months, with 
worsening cough, production of white sputum, worsening shortness of breath and reduced exercise 
tolerance from 300 yards to 100 yards on the flat. Patient is managed by her General Practitioner for 
the mainstay and exacerbation symptoms are generally treated with antibiotics which appeared to 
improve her symptoms but not fully resolve them.      
Patient 2.  Twenty years following her first presentation of vasculitis, the patient presented to the 
specialist Alpha-1-Antitrypsin Deficiency clinic with a diagnosis of PI*SZ alpha-1-antirypsin deficiency, 
identified through family screening. At the time of review, the patient was well and had 
unremarkable examination findings. The most recent serology showed an eosinophil count of 
0.3x109/L and normal inflammatory markers, IgE 9 ku/L, negative ANA, negative ANCA, weakly 
positive smooth muscle antibodies and normal liver function. The most recent imaging showed no 
evidence of emphysema on CT thorax.   
Patient 2 remains under the care of a specialist rheumatology team whom she sees regularly and 
during exacerbations. She reports a baseline of persistent fatigue with mild exacerbation of the 
vasculitis once yearly on average. Exacerbations are typified by gradually increasing fatigue followed 
by cough with minimal white sputum and increasing shortness of breath. Low grade fever, nausea, 
joint and back pain, and palpitations are also common features of her exacerbations. Sinus 
symptoms include pain, headache and serous yellow discharge with occasional bloody discharge. 
Patient 2 adopts a largely self-management strategy with mild exacerbations, she checks for 
reversibility in peak flow to salbutamol and tests her urine for blood and protein. If peak flow 
demonstrates no reversibility and her urine dip is positive for blood and protein, she manages this by 
increasing prednisolone to 20 or 30mg for up to three days and then continues or titrates down 
depending on response. She also seeks advice from her General Practitioner or Rheumatologist.   
DISCUSSION including very brief review of similar published cases (how many similar cases have 
been published?)   
Here we describe the rare occurrence of eosinophillic granulomatosis with polyangiitis in two 
patients with PI*SZ alpha 1-antitrypsin deficiency. In this case series, both patients presented with 
distinctive clinical features of EGPA. Both meet four out of six criteria for classification of EGPA 
according to ACR: asthma, eosinophilia >10%, neuropathy, non-fixed pulmonary infiltrates, paranasal 
sinus abnormalities, extravascular eosinophil infiltration on biopsy.[3] In the absence of validated 
diagnostic criteria, the ACR classification is useful for the consideration of essential characteristics 
for EGPA, however it is important to underline that this classification is not designed as diagnostic 
criteria.[4] Since our patients exhibited the majority of classification criteria, and in both cases had 
their diagnosis given to them by an appropriate specialist (rheumatologist) we believe the diagnosis 
of EGPA is accurate, but acknowledge that certainty is difficult in the absence of specific criteria 
against which to judge. A particularly desirable investigation might have been histology, which was 
inconclusive in patient 2. 
Investigations demonstrated markedly high eosinophils with raised inflammatory markers in both 
cases. Both patients, though diagnosed twenty years apart, have been treated successfully with 
high-dose steroids and azathioprine, though exacerbation symptoms manifest intermittently in both. 
As a rare and complex condition it is important to highlight the importance of specialist input into 
the management of patients with EGPA. In this case series patient 1 is largely managed by the GP 
and patient 2 has over time adopted a supervised self-management approach. The role of the 
specialist team is fundamental to safe and expert management of this complex chronic disease. 
Failure to involve specialists in the ongoing care of such patients is expressly discouraged.  
The coexistence of AATD and vasculitis is shown to be strongly associated with expression of the Z 
deficiency allele.[11,12] In such cases, patients are often positive for anti-proteinase 3 (PR3) 
antibodies and cANCA, a characteristic feature of GPA.[11,12] Evidence has also shown that 
expression of the S deficiency allele may be associated with other forms of vasculitis.[7] PI*SS or 
PI*SZ patients demonstrate a tendency to be pANCA positive.[7] pANCA positive status is often 
found in conjunction with positive anti-myeloperoxidase (MPO) antibodies; this occurs in 
approximately 40% of EGPA cases[2,3,4] such that the majority of EGPA patients, like our presented 
cases,  do not exhibit anti-MPO antibodies. Nevertheless, an association between EGPA and AATD 
may exist and the occurrence of EGPA in the two PI*SZ AATD patients described raises two 
questions; is there an association between the PI*SZ phenotype and vasculitis, and is this distinct 
from the association already established  between ANCA positive vasculitis (GPA) and  PI*ZZ?   The 
generalised nature of vasculitis symptoms, and indeed of AATD, may mean that diagnosis is missed 
initially and biochemical investigations are required; these  eventually led to diagnosis in our 
presented cases. Clinicians should therefore consider the possibility of AATD as a possible causative 
or exacerbating factor in EGPA, particularly when the vasculitic presentation is severe or 
accompanied by additional signs of AATD. Given the strength of evidence for an association between 
AATD and other forms of vasculitis, mainly GPA, further investigation into the association between 
AATD and EGPA is warranted. If additional evidence were to emerge in support of an association 
between AATD and EGPA, it would strengthen the argument for early screening.   
It is also interesting to speculate whether AATD would alter the management of vasculitis. Specific 
therapy for AATD does exist, in the form of intravenous supplementation of AAT, known as 
augmentation therapy. This treatment may slow the progression of emphysema [Chapman et al, 
Lancet Resp Med (2015)] and is also an accepted way to manage episodes of panniculitis [Blanco et 
al, OrphaNet J Rare Dis (2011)]. A single case of concurrent vasculitis and PiZZ AATD has also been 
reported where the vasculitis responded to augmentation therapy [Dowd et al, J Am Acad Derm 
(1995)], though this did not appear to be a case of EGPA. The role of augmentation in vasculitis 
unrelated to AATD is unclear; theoretically it might limit the damage from neutrophil elastase 
release in the inflamed vasculitic areas. Indeed AAT activity has been shown to be low in vessel walls 
of GPA patients [Mota et al, Rheumatol Int (2014)], thus giving a rationale for use of AAT 
augmentation in this condition. However there have been no reports of such management in the 
literature to our knowledge, thus this also remains an area for future research. 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points  
• Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic inflammatory condition which 
affects multiple organs.  
• Eosinophilia and asthma are both associated with EGPA.  
• Presenting symptoms may be non-specific but marked eosinophilia and raised inflammatory 
markers should raise the suspicion of EGPA.  
• Alpha 1 antitrypsin deficiency has previously shown an association with vasculitis.  
• More research is required to determine whether there is an association between the PI*SZ 
phenotype and EGPA.   
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